-
NAVB Dashboard
- Financials
- Filings
-
Holdings
- Transcripts
-
ETFs
- Insider
- Institutional
- Shorts
Navidea Biopharmaceuticals (NAVB)
Company Profile
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 3.86 mm | 3.86 mm | 3.86 mm | 3.86 mm | 3.86 mm | 3.86 mm |
Cash burn (monthly) | 759.68 k | 61.33 k | 751.78 k | 882.34 k | 3.42 mm | 809.48 k |
Cash used (since last report) | 11.26 mm | 908.82 k | 11.14 mm | 13.07 mm | 50.62 mm | 12.00 mm |
Cash remaining | -7.39 mm | 2.96 mm | -7.28 mm | -9.21 mm | -46.76 mm | -8.13 mm |
Runway (months of cash) | -9.7 | 48.2 | -9.7 | -10.4 | -13.7 | -10.0 |
13F holders | Current |
---|---|
Total holders | 21 |
Opened positions | 5 |
Closed positions | 12 |
Increased positions | 8 |
Reduced positions | 3 |
13F shares | Current |
---|---|
Total value | 138.02 mm |
Total shares | 1.50 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
STT State Street | 412.74 k | $37.97 mm |
Allred Capital Management | 293.84 k | $27.03 mm |
Vanguard | 276.49 k | $25.44 mm |
Susquehanna International | 125.87 k | $11.58 mm |
BLK BlackRock | 112.93 k | $10.39 mm |
Geode Capital Management | 101.00 k | $9.29 mm |
Two Sigma Securities | 59.31 k | $5.46 mm |
Boothbay Fund Management | 40.00 k | $3.68 mm |
NTRS Northern Trust | 39.41 k | $3.63 mm |
Pathstone Family Office | 10.04 k | $924.00 k |
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
27 Nov 23 | Scott John K Jr. | Series G Redeemable Preferred Stock | Other | Dispose J | No | No | 0 | 2,270 | 0.00 | 0 |
27 Nov 23 | Scott John K Jr. | Series J Convertible Preffered Stock Common Stock | Other | Acquire J | No | No | 100 | 64,289 | 6.43 mm | 64,289 |
27 Nov 23 | Scott John K Jr. | Series I Convertible Preferred Stock Common Stock | Other | Dispose J | No | No | 1000 | 2,400 | 2.40 mm | 0 |
16 Nov 23 | Jill Stefanelli | Common Stock | Grant | Acquire A | No | No | 0 | 416,667 | 0.00 | 941,667 |
16 Nov 23 | Jill Stefanelli | Common Stock | Grant | Acquire A | No | No | 0 | 275,000 | 0.00 | 525,000 |
16 Nov 23 | Dana J Moss | Common Stock | Grant | Acquire A | No | No | 0 | 416,667 | 0.00 | 866,667 |
16 Nov 23 | Dana J Moss | Common Stock | Grant | Acquire A | No | No | 0 | 200,000 | 0.00 | 450,000 |
10 Nov 23 | Craig Dais | Common Stock | Grant | Acquire A | No | No | 0 | 973,633 | 0.00 | 973,633 |